Willow vs Hims & Hers: GLP-1 Prices Compared
Willow and Hims & Hers do not sell the same product here: Willow sells compounded semaglutide injection (from $299/mo) and compounded tirzepatide injection (from $399/mo); Hims & Hers sells Wegovy injection ($238 first month) and Zepbound injection ($338 first month). Both sell semaglutide and tirzepatide, as different products: compounded semaglutide injection at Willow, Wegovy injection at Hims & Hers; compounded tirzepatide injection at Willow, Zepbound injection at Hims & Hers. What each sells here: Willow, compounded GLP-1s only; Hims & Hers, FDA-approved brand-name GLP-1s only. Compounded GLP-1s are not FDA-approved. Prices checked Oct 15, 2026 and Oct 20, 2026.
Every cash quote was checked on or after . Each quote shows its own check date. A quoted price is not a recommendation of a seller, a product or a dose. How we source prices
What Willow and Hims & Hers each sell
Both sell semaglutide and tirzepatide, as different products: compounded semaglutide injection at Willow, Wegovy injection at Hims & Hers; compounded tirzepatide injection at Willow, Zepbound injection at Hims & Hers.
Compounded semaglutide injection
Advertised entry price
from $299/moSupply period unverified; excluded from cost ranking.
Checked
Compounded semaglutide via Willow
Willow · Sourced provider quote
monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage
Price conditions
monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage
Weekly injection, or a daily under-the-tongue tablet at the same starting price. Willow publishes no price per dose. Available in 36 states. Compounded; not FDA-approved.
Compounded tirzepatide injection
Advertised entry price
from $399/moSupply period unverified; excluded from cost ranking.
Checked
Compounded tirzepatide via Willow
Willow · Sourced provider quote
monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage
Price conditions
monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage
Weekly injection, or a daily dissolving tablet from $399 a month (a purchase button on Willow's tablet page shows $299). Willow publishes no price per dose. Available in 36 states. Compounded; not FDA-approved.
Wegovy injection
Advertised entry price
$238 first monthCalculated: $199 medication + $39 introductory membership/provider fee. Charges billed separately.
Membership then $149/month, plus medication.
Separate billing cycles; excluded from cost ranking.
Checked
Wegovy pen via Hims
Hims & Hers · Sourced provider quote
Price conditions
Calculated: $199 medication + $39 introductory membership/provider fee
Medication starts at $199 a month if prescribed; Hims states no end date for this price. The separate required membership is $39 for the first month, then automatically renews at $149/month. Maintenance-dose total not verified; availability and eligibility vary.
Membership then $149/month, plus medication.
Zepbound injection
Advertised entry price
$338 first monthCalculated: $299 medication + $39 introductory membership/provider fee. Charges billed separately.
Membership then $149/month, plus medication.
Separate billing cycles; excluded from cost ranking.
Checked
Zepbound vial via Hims
Hims & Hers · Sourced provider quote
Price conditions
Calculated: $299 medication + $39 introductory membership/provider fee
Medication starts at $299 a month if prescribed; Hims lists the Zepbound KwikPen from $299 as well. The separate required membership is $39 for the first month, then automatically renews at $149/month. Hims' treatment list also shows Zepbound at $1,899/mo without naming a dose or form. Maintenance-dose total not verified.
Membership then $149/month, plus medication.
Compounded GLP-1s are not FDA-approved. Compounded drugs are not FDA-approved: the FDA does not review them for safety, effectiveness or quality before they are marketed. FDA: concerns with unapproved GLP-1 drugs used for weight loss
All Willow and Hims & Hers offers
Both sellers' quotes in one table, lowest 30-day cost first where the seller states its supply.
Search by medication, provider or treatment goal. Examples follow.
4 offers · US self-pay
This order ignores commission. Partner links may earn us a referral fee.
- Wegovy pen via Hims
Semaglutide · Telehealth (branded)
Advertised price$238 first monthCalculated: $199 medication + $39 introductory membership/provider fee. Charges billed separately.
Membership then $149/month, plus medication.
Separate billing cycles; excluded from cost ranking.
Checked
Maintenance priceView offerNo separate dose price verified
Price conditions & source
Medication starts at $199 a month if prescribed; Hims states no end date for this price. The separate required membership is $39 for the first month, then automatically renews at $149/month. Maintenance-dose total not verified; availability and eligibility vary.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price source - Zepbound vial via Hims
Tirzepatide · Telehealth (branded)
Advertised price$338 first monthCalculated: $299 medication + $39 introductory membership/provider fee. Charges billed separately.
Membership then $149/month, plus medication.
Separate billing cycles; excluded from cost ranking.
Checked
Maintenance priceView offerNo separate dose price verified
Price conditions & source
Medication starts at $299 a month if prescribed; Hims lists the Zepbound KwikPen from $299 as well. The separate required membership is $39 for the first month, then automatically renews at $149/month. Hims' treatment list also shows Zepbound at $1,899/mo without naming a dose or form. Maintenance-dose total not verified.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price source - Maintenance priceView offer
No separate dose price verified
Price conditions & source
Advertised price: monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage
Weekly injection, or a daily under-the-tongue tablet at the same starting price. Willow publishes no price per dose. Available in 36 states. Compounded; not FDA-approved.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price source - Maintenance priceView offer
No separate dose price verified
Price conditions & source
Advertised price: monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage
Weekly injection, or a daily dissolving tablet from $399 a month (a purchase button on Willow's tablet page shows $299). Willow publishes no price per dose. Available in 36 states. Compounded; not FDA-approved.
Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the provider. A listed offer does not confirm eligibility or stock.
Read the advertised-price source
Read prices in context. Compare the same product, dose, and payment terms. A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes with documented supply periods, converted to 30 days. Other prices are unranked references. Dose changes, introductory terms and added fees affect what you pay.
Missing prices are not estimated. A listed maintenance dose is not a dosing recommendation.
The FDA declared the tirzepatide (December 2024) and semaglutide (February 2025) shortages resolved, ending the exemption that let pharmacies mass-produce compounded copies, and the 503A/503B enforcement-discretion grace periods ended in 2025. The FDA is now actively enforcing (warning letters and takedowns, including a September 2026 warning letter to Empower Pharmacy, a large compounder, over products it called essentially copies of approved semaglutide and tirzepatide), and in 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list (the public comment period, extended 30 days, closed July 30, 2026; a final decision is pending). Liraglutide is different: it is still on the FDA drug shortage list (brand Victoza and Saxenda in limited supply, generics available, as of September 2026). Compounded GLP-1s are not FDA-approved and are now generally limited to narrow, patient-specific 503A prescriptions, so broad low-cost availability has largely wound down. They also carry safety risks the branded products do not: FDA adverse-event reports, at least one sterility recall (ProRx, October 2025), and counterfeit product found in the US supply chain, so a low price is not a low-risk signal. Prices and availability below may lag these changes; confirm current terms with the provider.
Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.
Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.
Willow vs Hims & Hers: common questions
Is Willow or Hims & Hers cheaper for GLP-1 medication?
They do not sell the same product here, so neither is cheaper for the same medication. Only Willow: Compounded semaglutide injection from $299/mo; Compounded tirzepatide injection from $399/mo. Only Hims & Hers: Wegovy injection $238 first month ($199 medication + $39 first-month membership/provider fee); Zepbound injection $338 first month ($299 medication + $39 first-month membership/provider fee). Both sell semaglutide and tirzepatide, as different products: compounded semaglutide injection at Willow, Wegovy injection at Hims & Hers; compounded tirzepatide injection at Willow, Zepbound injection at Hims & Hers. A compounded product is not a cheaper version of an FDA-approved brand; it is a different, unapproved product.
Do Willow and Hims & Hers sell FDA-approved GLP-1s or compounded versions?
What each sells here: Willow, compounded GLP-1s only; Hims & Hers, FDA-approved brand-name GLP-1s only. Compounded GLP-1s are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality.
What do Willow and Hims & Hers prices include?
Willow, compounded semaglutide injection: from $299/mo, monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage. Willow, compounded tirzepatide injection: from $399/mo, monthly subscription that renews until cancelled; physician, medication, care team and shipping included; price varies by dosage. Hims & Hers, Wegovy injection: $238 first month ($199 medication + $39 first-month membership/provider fee); membership then $149/month, plus medication. Hims & Hers, Zepbound injection: $338 first month ($299 medication + $39 first-month membership/provider fee); membership then $149/month, plus medication.
When were Willow and Hims & Hers prices last checked?
Prices checked Oct 15, 2026 and Oct 20, 2026. Each quote links the seller's own page it was read from. A quote not rechecked within 21 days is kept as a dated reference and is no longer stated as a current price.